EU panel rejects Pfizer's tanezumab for osteoarthritis pain

Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor tanezumab looks to have been dashed after the EMA's human medicines committe

Thumbs-down from FDA experts for Pfizer/Lilly's painkiller t...

After more than a decade of fraught clinical development it looks like the end of the line for Pfizer/Lilly painkiller tanezumab, which promised to be an alternative to addictive opioid pai

FDA worried about Pfizer/Lilly pain drug safety ahead of key...

After a long and troubled development the fate of Pfizer/Lilly’s tanezumab painkiller injection is in the balance ahead of a key meeting of advisers later this week. 

FDA starts review of Pfizer, Lilly’s non-opioid painkiller

UK biotech gets grant for further trial of osteoarthritis dr...

UK biotech AKL Research and Development (AKLRD) has received a grant from a UK government-backed innovation body to develop its potentially “game changing” osteoarthritis drug.